Fierce Pharma August 23, 2024
Ayla Ellison, Kevin Dunleavy

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities.

The Supreme Court overturned the doctrine...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Pharma, Pharma / Biotech, Regulations, Trends
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Walgreens PE deal back on the table: 5 things to know
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more

Share This Article